ArticleScientific reports2025
Machine learning-assisted screening of clinical features for predicting difficult-to-treat rheumatoid arthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Baseline pain, fatigue, and sleep quality predict 12-week pain improvement in inflammatory arthritis: retrospective real-world analysis of a digital health application cohort.Rheumatology international · 2026Article
- Comparative evaluation of large language models on multiple-choice and image-based rheumatology questions.Rheumatology international · 2025Article
- Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To identify clinical features that predict the risk of meeting difficult-to-treat (D2T) rheumatoid arthritis (RA) definition in advance. This retrospective analysis included RA patients from the ATTRA registry who initiated biologic (b-) or targeted synthetic (ts-) disease-modifying anti-rheumatic drugs (DMARDs) between 2002 and 2023. Patients with D2T RA met the EULAR criteria, while controls achieved sustained remission, defined as a Simple Disease Activity Index (SDAI) < 3.3 and a Swollen Joint Count (SJC) ≤ 1, maintained across two consecutive visits 12 weeks apart. Patients were assessed at baseline and at one and two years before fulfilling the D2T RA definition. Predictive models were developed using machine learning techniques (lasso and ridge logistic regression, support vector machines, random forests, and XGBoost). Shapley additive explanation (SHAP) values were used to assess the contribution of individual variables to model predictions. Among 8,543 RA patients, 641 met the criteria for D2T RA, while 1,825 achieved remission. The machine learning models demonstrated an accuracy range of 0.606-0.747, with an area under the receiver operating characteristic curve (AUC) of 0.656-0.832 for predicting D2T RA. SHAP analysis highlighted key predictive variables, including disease activity measures (DAS28-ESR, CDAI, CRP), patient-reported outcomes (HAQ), and the duration of b/tsDMARD treatment. We identified clinical features predictive of D2T RA at baseline and up to one year before meeting the formal criteria. These findings provide valuable insights into early indicators of D2T RA progression and support the importance of earlier recognition and timely therapeutic intervention to improve long-term patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.